Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Completed · Phase 2

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with indolent lymphoma, Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia.

Key facts

Study ID

NCT00005579

Run by

University of Vermont

Starts

1998-06-01

Expected to finish

2003-02-01

Last updated by the study team

2013-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Marlene and Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States
• Vermont Cancer Center — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.